Yahoo
Tokyo - Delayed Quote JPY

Olympus Corporation (7733.T)

1,742.00 -27.00 (-1.53%)
At close: October 30 at 3:30:00 PM GMT+9
Chart Range Bar
Loading chart for 7733.T
  • Previous Close 1,769.00
  • Open 1,750.00
  • Bid 1,741.00 x --
  • Ask 1,751.00 x --
  • Day's Range 1,741.50 - 1,785.50
  • 52 Week Range 1,302.50 - 2,210.50
  • Volume 4,914,900
  • Avg. Volume 4,923,695
  • Market Cap (intraday) 1.851T
  • Beta (5Y Monthly) 0.26
  • PE Ratio (TTM) 28.46
  • EPS (TTM) 61.20
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield 30.00 (1.72%)
  • Ex-Dividend Date Mar 30, 2027
  • 1y Target Est 2,084.62

Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, “Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.

www.olympus.co.jp

28,138

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

7733.T
10.46%
Nikkei 225 (^N225)
25.73%

1-Year Return

7733.T
6.83%
Nikkei 225 (^N225)
23.31%

3-Year Return

7733.T
7.13%
Nikkei 225 (^N225)
106.18%

5-Year Return

7733.T
25.48%
Nikkei 225 (^N225)
119.05%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 240.4B
Earnings 19.1B
Profit Margin 7.95%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
100B
200B
6.0%
7.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

1,800.00
2,084.62 Average
1,742.00 Current
3,300.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.49%

  • Return on Assets (ttm)

    6.33%

  • Return on Equity (ttm)

    10.57%

  • Revenue (ttm)

    1.04T

  • Net Income Avi to Common (ttm)

    78.28B

  • Diluted EPS (ttm)

    61.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    118.54B

  • Total Debt/Equity (mrq)

    42.64%

  • Levered Free Cash Flow (ttm)

    17.3B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: